Drug Topics
JULY 1, 2025
Interest in community pharmacy practice is declining as pharmacists seek roles with better work-life balance, greater autonomy, and more meaningful patient care opportunities.
PharmaVoice
JULY 1, 2025
Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JULY 1, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
PharmaVoice
JULY 1, 2025
The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
JULY 1, 2025
Jon Easter, RPh, discusses pharmacists’ ability to improve patient engagement in diabetes care following his presentation at the American Diabetes Association’s 85th Scientific Sessions.
Hospital Pharmacy Europe
JULY 1, 2025
With the impact of digital technologies on healthcare provision and the workforce ramping up, Matthew Spence, clinical digital lead for medicines management and pharmacy services at Leeds Teaching Hospitals NHS Trust, offers practical tips and strategies based on insights and initiatives from his own hospital to support pharmacy teams in navigating digital transformation.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Pharma
JULY 1, 2025
In a quarterly update, the FDA said it’s evaluating the need for regulatory action on argenx’s Vyvgart Hytrulo after observing a potential signal of “severe worsening” of CIDP. But analysts are brushing off the risk.
Drug Topics
JULY 1, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
pharmaphorum
JULY 1, 2025
Reports suggest a new framework for medicine reviews and a push to reduce NHS reliance on overseas-trained staff will feature in the 10-year plan.
Pharmacy Times
JULY 1, 2025
CARTITUDE-1 trial reveals cilta-cel's potential in achieving long-term remission for relapsed/refractory multiple myeloma, sparking discussions on curative possibilities.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JULY 1, 2025
An experimental psychedelic therapy from the U.K. company Beckley Psytech significantly reduced symptoms of treatment-resistant depression in a mid-stage trial, newly released data show, raising expectations for a class of drugs racing toward potential approval by U.S. regulators. Companies like Beckley, Atai Life Sciences, and Compass Pathways — the first two are in the process of merging — are now vying to bring psychedelic therapies to market at a time when the regulatory
Pharmacy Times
JULY 1, 2025
Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure.
STAT
JULY 1, 2025
WASHINGTON — Health secretary Robert F. Kennedy Jr. has assembled a team that he says will work on ways to expand a federal program aimed at compensating people who have been injured by vaccines, though his power to make big changes without congressional action is unclear. “We just brought a guy in this week who is going to be revolutionizing the [National] Vaccine Injury Compensation program,” Kennedy said in an interview with Tucker Carlson posted Monday.
Pharmacy Times
JULY 1, 2025
Courtney Cavalieri, PharmD, BCOP, and Kenneth Tham, PharmD, BCOP, discuss how pharmacists play a crucial role in managing biliary tract cancer patients by providing expertise on biomarker testing, treatment selection between targeted therapies like FGFR and HER2 inhibitors, developing monitoring protocols for unique toxicities such as hyperphosphatemia, and educating patients on side effect management to optimize treatment outcomes in this rare cancer type.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JULY 1, 2025
Beyond AI hype: How dynamic study forecasting is helping pharma gain control of clinical trial enrolment Nicole.
Pharmacy Times
JULY 1, 2025
Gianni Scappaticci, PharmD, BCOP, outlines a personalized, evidence-based approach to managing steroid-refractory chronic graft-versus-host disease (cGVHD) in a post–haploidentical transplant patient, highlighting the rationale for using ruxolitinib, belumosudil, or their combination based on disease progression and fibrotic features.
Pharmafile
JULY 1, 2025
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, a new selective delta opioid receptor agonist. The appeal marks a significant milestone in the company’s mission to develop non-addictive alternatives for neuropathic pain. PN6047 is a small molecule that selectively targets the delta opioid […] The post PharmNovo submits CTA for non-addictive neuropathic pain therapeutic appeared first on Pharma
Hospital Pharmacy Europe
JULY 1, 2025
A batch of tamoxifen 20mg film-coated tablets has been recalled as a precautionary measure following the identification of a ‘dissolution failure’ during stability testing, its manufacturer has announced. Wockhardt UK Limited has recalled batch number HZ10030 (expiry date: 30/04/2027), distributed in packs of 30 tablets. The batch of tamoxifen, which is used primarily to treat breast cancer , was first distributed on 22 August 2024.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
JULY 1, 2025
Obecabtagene autoleucel shows promising efficacy and safety in treating relapsed/refractory B-ALL, benefiting patients of all ages, including older adults.
Drug Topics
JULY 1, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
The Nontraditional Pharmacist
JULY 1, 2025
Chapters 00:00 Navigating Nontraditional Pharmacy Roles 02:54 Transitioning from Regulatory Affairs to Clinical Operations 05:45 Understanding Clinical Operations and Its Importance 08:54 The Role of Pharmacists in Clinical Trials 12:07 Career Pathways for Pharmacists in Clinical Operations 14:59 Networking and Mentorship in Nontraditional Pharmacy 17:53 Future Aspirations in the Pharmaceutical Industry Want to see Brendan’s Original Interview?
pharmaphorum
JULY 1, 2025
The proposed merger between Beckley Psytech and atai is unlocked as a psychedelic for depression hits all its endpoints in a phase 2b trial.
PharmD Live
JULY 1, 2025
Introduction: Why Patient Consent Matters More Than Ever in RPM Remote Patient Monitoring (RPM) is revolutionizing chronic care management by improving patient outcomes and unlocking sustainable revenue streams for healthcare providers. But in 2025, RPM patient consent compliance is more than a billing formality; it is a legal, regulatory, and ethical imperative.
pharmaphorum
JULY 1, 2025
Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Oncology -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -Whi
European Pharmaceutical Review
JULY 1, 2025
The European Commission has granted approval of the first subcutaneous, once-monthly octreotide for the rare, chronic disease acromegaly. Oczyesa ® (CAM2029), octreotide subcutaneous depot, is indicated as a maintenance treatment in adult patients who are responsive to and tolerate somatostatin analogs treatment. It is self-administered subcutaneously once-monthly via a pre-filled autoinjector pen.
pharmaphorum
JULY 1, 2025
Explore how North Carolina's Research Triangle is driving biotech innovation, attracting major pharma players, and strengthening local manufacturing—insights from BIO 2025 with Kyle Touchstone and Laura Rowley.
Fierce Pharma
JULY 1, 2025
The U.S. Supreme Court ruled to protect a measure of the Affordable Care Act that supports preventative services such as pre-exposure prophylaxis (PrEP) HIV meds, offering good news for Gilead as it launches its long-acting PrEP drug Yeztugo.
Pharmaceutical Commerce
JULY 1, 2025
Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how patient and caregiver insights shape drug development, regulatory decisions, and payer considerations in rare diseases.
PQA
JULY 1, 2025
PQA identified six objectives to advance medication therapy management (MTM) quality and measurement, highlighted in the first blog on PQA’s MTM initiative. One ongoing objective is to increase the patient-centeredness of MTM services in the Medicare Part D MTM program. Another is to conceptualize new MTM quality measures. A key strategy to meet these objectives is the development of an MTM patient-reported outcome measure (PROM) aligned with the Part D MTM program goals for comprehensive medica
Pharmaceutical Technology
JULY 1, 2025
Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.
Pharmafile
JULY 1, 2025
SphingoTec has announced new findings validating the clinical utility of its kidney biomarker proenkephalin A 119-159 (PenKid) in assessing graft function trajectories following kidney transplantation. The study, published in Transplant International, positions penKid as a highly reliable and early predictor of delayed graft function (DGF), surpassing traditional biomarkers such as serum creatinine (SCr) in both […] The post SphingoTec’s PenKid leads the way in early detection of delayed g
Fierce Healthcare
JULY 1, 2025
Following a record-breaking "vote-a-rama" and tie-breaker vote, the massive bill now returns to the House where it is expected to face more scrutiny.
pharmaphorum
JULY 1, 2025
Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Oncology -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -Whi
Expert insights. Personalized for you.
380 
Let's personalize your content